Johnson & Johnson (JNJ)

150.13
NYSE : Health Technology
Prev Close 150.09
Day Low/High 149.15 / 150.64
52 Wk Low/High 126.10 / 154.50
Avg Volume 6.35M
Exchange NYSE
Shares Outstanding 2.63B
Market Cap 395.02B
P/E Ratio 26.66
Div & Yield 3.80 (2.48%)
Want to Beef Up on Dividend Stocks? Here Are Some NOBL Opportunities

Want to Beef Up on Dividend Stocks? Here Are Some NOBL Opportunities

The S&P 500 has added these companies to the Dividend Aristocrats class of 2020.

Consider This Dividend Stock Money in the Bank

Consider This Dividend Stock Money in the Bank

People's United Financial is a 4.5%-yielding dividend aristocrat that's on a path to continued expansion.

Market Direction and Trading Volume, Resilient Boeing, Trading Costco

Market Direction and Trading Volume, Resilient Boeing, Trading Costco

Boeing's new estimate for the FAA's signing off on returning the 737 MAX to commercial skies has been pushed out until summer, June or July? Is that really that bad? Perhaps... this is a positive.

The Week Ahead: Davos, Impeachment, PMI and 25 Key Earnings Reports to Watch

The Week Ahead: Davos, Impeachment, PMI and 25 Key Earnings Reports to Watch

Almost 200 companies are slated to report quarterly results, including 43 S&P 500 constituents.

3 Powerhouse Pharma Stock Favorites

3 Powerhouse Pharma Stock Favorites

These healthcare stalwarts look attractive for growth and income.

Johnson & Johnson Finally Shakes Off Its Bad News 'Overhang'

Johnson & Johnson Finally Shakes Off Its Bad News 'Overhang'

It looks like JNJ has its swagger back.

J&J Raised at Morgan Stanley

Jim Cramer: Don't Be an Armageddonist and Live in Fear of a Crash

Jim Cramer: Don't Be an Armageddonist and Live in Fear of a Crash

Having a bad game does not mean you quit forever. It just means it is time to regroup and rethink strategy.

Jim Cramer: Here's Why the Market Hasn't Stopped Rallying

Jim Cramer: Here's Why the Market Hasn't Stopped Rallying

These are the 10 reasons why we keep going up, despite all the bad news.

Novice Trade: Johnson & Johnson

Novice Trade: Johnson & Johnson

I have been using these down days to buy calls and then selling on the pops up the next.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Amazon Is a Trade for Now, The Fed Pipes Down: Market Recon

Amazon Is a Trade for Now, The Fed Pipes Down: Market Recon

Most important is that the Fed felt the need earlier this week to expand it's minimum offering for overnight repo operations, while also increasing the 14 day repos.

Is the Worst Over for Johnson & Johnson?

Is the Worst Over for Johnson & Johnson?

A lot of investing is just waiting until the market hates good companies.

Jim Cramer: The Soundness of My Methods

Jim Cramer: The Soundness of My Methods

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.

Earnings Season Round 2 Starts Today

Earnings Season Round 2 Starts Today

The majority of the S&P 500 stocks will report in the next two weeks. Focus on individual stock picking, but keep stops tight.

Energy Stocks Are Getting Hammered

Energy Stocks Are Getting Hammered

There are myriad concerns across the energy complex, the most prevalent one centered around declining global growth reducing the demand for energy.

China Trade, Next Brexit Vote, Fed Action, Trading Lockheed: Market Recon

China Trade, Next Brexit Vote, Fed Action, Trading Lockheed: Market Recon

The Trump and Xi administrations are at least looking at the same page. That's more than nothing.

3 Earnings Reports Will Be Key for the Market Next Week

3 Earnings Reports Will Be Key for the Market Next Week

There is a good foundation for more positive action in the week ahead.

Arrowhead Pharmaceuticals Is Flying Higher on the Charts

Arrowhead Pharmaceuticals Is Flying Higher on the Charts

Before I give my recommendation I want to visit with the charts and indicators.

For Boeing and Johnson & Johnson: Where There's Smoke, There's Fire

For Boeing and Johnson & Johnson: Where There's Smoke, There's Fire

Both BA and JNJ appear to have made decisions in which the bottom line took precedent over what they stand for as a company.

Jim Cramer: Here's How You Get a Not as Bad as Feared Quarter

Jim Cramer: Here's How You Get a Not as Bad as Feared Quarter

I have the answer behind the conundrum that forces stocks up that should be going lower.

Jim Cramer: Netflix and CSX Lead the 'NABAF' Earnings Story

Jim Cramer: Netflix and CSX Lead the 'NABAF' Earnings Story

These stocks's earnings were 'not as bad as feared,' and here are some more names that pushed the NABAF narrative.

Jim Cramer: The Market Is Lapping Up These Stocks

Jim Cramer: The Market Is Lapping Up These Stocks

There are plenty of senior growth companies that can still move higher.

Key Market Observations

As mentioned earlier, breadth was only 2-1 positive with UnitedHealth , JPMorgan and Johnson & Johnson responsible for a large portion of the market's gains. Bond yields rose, aiding the rate-sensitive banks (who generally met expectations). FANG ha...

Jim Cramer: Here's What We Can Bask in Today

Jim Cramer: Here's What We Can Bask in Today

On days like today you realize how much of this market has been mauled by the bear.

Advancers Over Decliners

"Only" about 2-1 advancers over decliners as UnitedHealth Care , JP Morgan and Johnson & Johnson account for a disproportionate amount of the market's rally.

Valuation and 2 Names to Watch Into Earnings: Market Recon

Valuation and 2 Names to Watch Into Earnings: Market Recon

Citigroup and Lululemon are on the radar this morning.

Fed 'Blindsided' Again, Peloton's No Bargain, Trading Jabil: Market Recon

Fed 'Blindsided' Again, Peloton's No Bargain, Trading Jabil: Market Recon

Does the Fed just keep injecting liquidity into money markets every single night forever?

Jim Cramer: Here's Why the Market's So Feckless and Reactive

Jim Cramer: Here's Why the Market's So Feckless and Reactive

So many companies -- like Netflix, Facebook and Johnson & Johnson -- are not trading on earnings per share, but on factors that are nearly impossible to quantify.

For Wealth and Safety Invest With a 'Shark'

For Wealth and Safety Invest With a 'Shark'

Four ETFs designed around Kevin O'Leary's growth, income and wealth preservation-oriented strategy.